Aileron Raises $30M From Existing Investors To Advance Pair Of Stapled Peptide Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
The Cambridge, Mass., biotech plans to bring a candidate for cancer into clinical development next year, while starting Phase Ib dose-finding research with its endocrinology disorder candidate.
You may also be interested in...
Aileron Overcoming Spirited Debate About Stapled Peptides
The new, promising class of drugs is rolling toward the clinic, but a respected research group recently thrust a stick in the spokes and prompted a call for wider access to the technology.
Roche Partners With Peptide Specialist Aileron For Five Targets
A $25 million upfront commitment could blossom into a deal worth as much as $1.1 billion plus royalties.
Corporate VC Funds Drive Innovation For Aileron’s Novel Stapled Peptide Technology
Aileron’s stapled peptides spark investment interest from four big pharma VC arms.